Bortezomib/dexamethasone
| Combination of | |
|---|---|
| Bortezomib | Proteasome inhibitor |
| Dexamethasone | Corticosteroid |
| Clinical data | |
| Trade names | Vel/Dexm, Vel-Dex, and Veldex |
| Legal status | |
| Legal status |
|
Bortezomib/dexamethasone is a combination drug against multiple myeloma.[1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid.
References[edit]
- ^ Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, et al. (February 2010). "Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma". Leukemia & Lymphoma. 51 (2): 236–42. doi:10.3109/10428190903452826. PMID 20001242. S2CID 25932724.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |